25E-NBOMe

Discovery

The parent compound 2C-E was first synthesized and self-assayed by Alexander Shulgin, documented in PiHKAL.^[8] The N-(2-methoxybenzyl) modification defining the NBOMe class was introduced by Ralf Heim at the Free University of Berlin in 2003, as part of doctoral research on radioligands for 5-HT₂A receptor imaging.^[2] Heim's work was pharmacological tool development — the N-benzylation dramatically increased receptor affinity, producing candidates for positron emission tomography. He did not investigate or anticipate recreational use.

Market emergence

NBOMe compounds appeared on illicit drug markets in the early 2010s,^[5] distributed by online research chemical vendors.^[9] 25E-NBOMe was first analytically confirmed from seized blotter papers in Poland in 2013.^[3] Throughout this period, NBOMe compounds were commonly sold as LSD, exploiting their microgram-range potency and blotter-compatible form^[6][9] — a misrepresentation that contributed to hospitalizations and fatalities involving 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe, though no deaths have been attributed specifically to 25E-NBOMe.

Prohibition

Regulatory action targeted the more prevalent congeners first. The United States permanently placed 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe in Schedule I in September 2016.^[10] 25E-NBOMe was not explicitly named but remains prosecutable under the Federal Analogue Act. The United Kingdom classified all N-benzylphenethylamine derivatives as Class A in June 2014, and Brazil explicitly scheduled 25E-NBOMe by name in February 2014 — among the first jurisdictions to do so.^[11]

Structural class

25E-NBOMe is a substituted phenethylamine and member of the 25x-NBOMe series — N-(2-methoxybenzyl) derivatives of the 2C compounds. It is derived from 2C-E by attaching a 2-methoxybenzyl group to the amine nitrogen, a modification that dramatically increases 5-HT₂A receptor affinity compared to the parent compound.^[12]

Molecular properties

The molecule consists of a 2,5-dimethoxyphenethylamine core with a 4-ethyl substituent on the aromatic ring and an N-(2-methoxybenzyl) group on the nitrogen. Three methoxy groups and the ethyl chain define the compound's lipophilicity and receptor binding characteristics. Definitive identification requires LC-MS/MS or NMR, as dominant mass spectral fragments overlap with related NBOMe compounds.^[3]

Stereochemistry

25E-NBOMe contains no chirality centers. The compound exists as a single achiral species; enantiomeric considerations do not apply.

Physical properties

No published characterization of physical properties (melting point, solubility, stability) exists for 25E-NBOMe in free base or salt form. The compound has been encountered exclusively as blotter paper preparations in forensic seizures.^[3]

Mechanism of action

25E-NBOMe acts as a full agonist at serotonin 5-HT₂A receptors — the primary molecular target responsible for hallucinogenic effects.^[1] It binds with very high potency at both 5-HT₂A and 5-HT₂C receptors, with negligible activity at monoamine transporters — a profile consistent with hallucinogenic activity without significant stimulant properties.^[1]

Activation of 5-HT₂A receptors on neurons in the prefrontal cortex increases glutamate release, proposed as the proximal mechanism underlying hallucinogenic perception.^[13] In rodent studies, the hallucinogenic-proxy behavior produced by 25E-NBOMe was blocked by a selective 5-HT₂A antagonist, confirming the receptor dependence of its effects.^[14]

Beyond serotonin activity, 25E-NBOMe modulates the dopamine system. Rodent research found it reduced dopamine levels in the nucleus accumbens while increasing D1 receptor expression and activating downstream signaling.^[14] Reward-seeking behavior in these animals was blocked by D1 receptor antagonism, suggesting a dopamine-dependent reinforcement pathway atypical for classical psychedelics.^[14] These findings are from male rodents only; relevance to human pharmacology is unestablished.

Pharmacokinetics

No human pharmacokinetic data exist for 25E-NBOMe. Bioavailability, peak concentration, half-life, and clearance have not been measured in any species.

NBOMe compounds as a class are inactive when swallowed — the specific mechanism remains unelucidated.^[5] Active routes include sublingual/buccal absorption, nasal insufflation, intravenous injection, and smoking.^[5] Sublingual onset is approximately 15 minutes, with total duration of 4–10 hours.^[15]

Liver metabolism studies identified 26 Phase I metabolites, with principal pathways including O-demethylation, N-dealkylation, and hydroxylation.^[16] The parent compound 2C-E was detected among these metabolites, confirming N-dealkylation as a major route.^[16] The specific liver enzymes responsible have not been identified, though O-demethylation in related compounds is generally attributed to CYP2D6 and CYP3A4.inferred

Where it acts

No neuroimaging studies have been conducted with 25E-NBOMe. In closely related 25I-NBOMe, administration increased extracellular dopamine, serotonin, and glutamate in the prefrontal cortex, with the hallucinogenic-proxy behavior selectively tied to increased glutamate release.^[13] This supports a model in which 5-HT₂A activation on cortical neurons disinhibits glutamate transmission, disrupting the brain's normal filtering of sensory information and increasing neural entropy.

25E-NBOMe also modulates the mesolimbic dopamine system, reducing dopamine levels in the nucleus accumbens while upregulating D1 receptors — a compensatory plasticity pattern that may engage reward circuitry atypical for classical psychedelics.^[14][17]

Why it matters

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that 5-HT₂A agonists reduce the brain's confidence in its existing predictions, loosening top-down constraints on perception and thought. As a potent full 5-HT₂A agonist, 25E-NBOMe would be expected to engage this mechanism, though no brain imaging data confirm it.citation needed

Separately, 5-HT₂A agonists in the psychedelic class promote rapid neural rewiring — new dendritic connections and synapse formation — via growth-factor signaling cascades. Whether 25E-NBOMe drives this neuroplasticity has not been tested directly, though its full agonist profile suggests comparable potential.citation needed

Toxicity

No controlled toxicity data exist for 25E-NBOMe specifically. No lethal dose has been established in any species, and no deaths have been attributed to 25E-NBOMe alone.safety citation needed

The NBOMe class produces a consistent pattern of toxic effects: rapid heart rate, high blood pressure, dangerously elevated body temperature, sweating, dilated pupils, agitation, seizures, and excited delirium.^[5][17][15] By class membership, 25E-NBOMe is presumed to carry comparable risks.

Animal studies show the broader NBOMe class causes developmental harm, tissue damage, cardiovascular toxicity, and behavioral changes.^[17] A subtle DNA-damaging effect was observed for 25B-NBOMe;^[18] whether this generalizes to 25E-NBOMe is unknown.

Psychological Risks

Acute psychological adverse effects documented for the NBOMe class include severe anxiety, panic attacks, psychosis-like states (hallucinations, paranoid thinking, thought disorganization), and violent agitation.^[5][17] Agitation and uncontrollable violent behavior are more prominent with NBOMe compounds than with classical psychedelics such as LSD or psilocybin, likely reflecting the broader receptor profile.^[17]

Persistent effects including HPPD (HPPD) and lasting psychosis have been reported for the NBOMe class. No published case reports of persistent psychological effects specific to 25E-NBOMe were identified.safety citation needed

Tolerance & Dependence

Rapid tolerance is expected via 5-HT₂A downregulation following repeated use.^[4] Cross-tolerance exists between psychedelic 5-HT₂A agonists, meaning recent use of LSD, psilocin, 25I-NBOMe, or other serotonergic psychedelics will blunt 25E-NBOMe's effects and vice versa.^[4]inferred

Physical dependence is not expected based on psychedelic class pharmacology. However, rodent studies demonstrated reward-seeking behavior with 25E-NBOMe via a D1 dopamine receptor pathway,^[14] providing preclinical evidence of reinforcement potential. No human dependence or withdrawal cases have been reported for 25E-NBOMe or the broader NBOMe class.

Drug Interactions

No human drug interaction studies exist for 25E-NBOMe. The following interactions are inferred from its mechanism of action.inferred

Serotonergic drugs: Combining a potent 5-HT₂A agonist with any drug that increases serotonin activity — including MAOIs, SSRIs, SNRIs, tricyclic antidepressants, lithium, tramadol, triptans, and MDMA — carries risk of serotonin syndrome.^[17][5]safety citation needed

Lithium: Anecdotally linked to increased seizure risk with serotonergic psychedelics. NBOMe compounds independently lower the seizure threshold, making this combination particularly dangerous.safety citation needed

CYP2D6 and CYP3A4 inhibitors: Drugs that inhibit these liver enzymes (fluoxetine, paroxetine, bupropion, ketoconazole) could theoretically slow clearance and increase toxicity risk.inferred

Stimulants: Co-use with cocaine or amphetamines would be expected to compound cardiovascular toxicity — dangerously high blood pressure, elevated body temperature, and rapid heart rate — through additive stimulation.inferred

Cannabis: May unpredictably intensify or alter the psychedelic experience.citation needed

Contraindications

No substance-specific contraindication data exist. The following are inferred from NBOMe class pharmacology.inferred

Heart conditions: The stimulant-like toxic effects (high blood pressure, rapid heart rate, blood vessel constriction) make 25E-NBOMe contraindicated in individuals with pre-existing cardiovascular disease.^[5]

Seizure disorders: NBOMe compounds lower the seizure threshold; epilepsy or any seizure predisposition is a contraindication.^[5][17]

Psychotic disorders: Personal or family history of schizophrenia or schizoaffective disorder is a contraindication given the psychosis-inducing potential of potent 5-HT₂A agonists.^[17]

Concurrent serotonergic medications: MAOIs, SSRIs, SNRIs, or lithium are contraindicated due to serotonin syndrome risk.safety citation needed

Liver impairment: 25E-NBOMe undergoes extensive liver metabolism;^[16] impaired liver function could reduce clearance and increase toxicity.

Pregnancy: Animal data show developmental harm from NBOMe exposure.^[17]

25E-NBOMe is not explicitly named in many controlled substance schedules but falls within structural analog provisions or catch-all structural definitions in most major jurisdictions. The more prevalent congeners — 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe — were scheduled by name, while 25E-NBOMe's legal status derives primarily from structural similarity provisions. Brazil is a notable exception, having explicitly listed 25E-NBOMe by name in 2014.

Analogue act considerations

In the United States, 25E-NBOMe's legal exposure rests on the Federal Analogue Act (21 U.S.C. § 813), which treats substances "substantially similar" to Schedule I compounds as Schedule I when intended for human consumption. With 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe permanently in Schedule I,^[10] 25E-NBOMe — differing only in the 4-position substituent — is a straightforward analogue act target. Case law on NBOMe analogue prosecutions has grown since 2014, though no published appellate decision specifically addressing 25E-NBOMe was identified.